Accuray Announces Approval of the Accuray Precision® Treatment Planning System by China's National Medical Products Administration
Accuray announced the approval of its Accuray Precision Treatment Planning System (TPS) by China's National Medical Products Administration (NMPA). This approval allows the system to be used with the CNNC-Accuray joint venture Tomo C radiation therapy system. This combination aims to provide precise radiotherapy treatments, expanding access for cancer patients in China. Suzanne Winter, CEO of Accuray, highlighted the system's benefits in addressing the high incidence of cancer in China. The Accuray Precision TPS facilitates rapid adaptation of treatment plans to changes in tumor characteristics and healthy tissue, enhancing treatment accuracy. The Tomo C platform includes helical imaging and radiation delivery with patented beam-shaping technology, optimizing radiation dose control.
- Approval of Accuray Precision TPS by China's NMPA.
- Availability of the TPS with Tomo C system expands treatment options in China.
- Potential to address the high incidence of cancer in China, which accounted for 25% of new cases globally in 2020.
- Enhances Accuray's portfolio and market access in China's Type B market.
- Provides medical teams with tools for precise and adaptable treatment plans, improving patient outcomes.
- The Tomo C system's advanced imaging and radiation delivery capabilities enable optimized radiation dose control, minimizing impact on healthy tissues.
- No immediate financial data provided to assess direct financial impact.
- Potential competition in the regional Type B market might affect market penetration.
- Dependence on regulatory approvals and compliance could pose risks for future product offerings.
Insights
The approval of the Accuray Precision® Treatment Planning System (TPS) by China's National Medical Products Administration (NMPA) represents a significant milestone for Accuray Incorporated. It paves the way for the company's joint venture with CNNC to start shipping the Tomo® C radiation therapy system, which could potentially boost revenue streams from the Chinese market. Given that China accounted for roughly
However, while the news is positive, investors should consider the competitive landscape. Companies like Varian Medical Systems and Elekta also have a strong foothold in the Chinese market. Accuray's ability to distinguish its product through superior precision, customization and speed of treatment planning will be critical in gaining market share. Additionally, the financial impact will depend on the company's ability to scale production and distribution effectively to meet local demand.
From a clinical perspective, the integration of the Accuray Precision Treatment Planning System with the Tomo C platform is a noteworthy advancement. The system's ability to adapt treatment plans based on real-time changes in tumor size, shape and location could significantly improve patient outcomes. This is especially beneficial for cancers with high variability in tumor positioning, such as lung and head and neck cancers. Clinicians will appreciate the enhanced capability to deliver precise radiation doses while minimizing exposure to surrounding healthy tissue.
Moreover, the inclusion of helical imaging and beam-shaping technology could make complex treatments such as total marrow irradiation more effective and safer. This approval and subsequent availability can potentially elevate the standard of care in Chinese oncology departments, offering new treatment options that might otherwise be inaccessible.
"We couldn't be more pleased about the approval of the Accuray Precision Treatment Planning System and the potential it represents, in combination with the Tomo C System, for cancer patients in
Continued Ms. Winter, "Customers in
The Accuray Precision TPS was developed to facilitate the creation and adaptation of precise treatment plans in less time. The planning solution enables clinicians to routinely incorporate modifications to treatment planning into the course of treatment to account for changes in tumor size, shape and location – as well as subtle changes in the location of organs and other healthy tissue – thereby increasing treatment precision.
The Tomo C platform features helical imaging and radiation delivery. With fully-integrated treatment planning, centralized data management and ultra-precise treatment delivery using patented beam-shaping technology, the system enables greater control of the radiation dose so it conforms precisely to the tumor and helps minimize dose to healthy tissue. The system is designed to enable medical care teams to optimize outcomes for standard radiation therapy indications including breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow irradiation.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations and goals regarding new products, services and innovations, expectations regarding our joint venture, and patient experiences and patient outcomes. These risks and uncertainties include, but are not limited to, the effect of the current global economic environment, including in connection to the COVID-19 pandemic, on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands; reliance on third party collaborators, partnerships, strategic alliances and joint ventures; and such other risks identified under the heading "Risk Factors" in company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 8, 2024, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
1https://pubmed.ncbi.nlm.nih.gov/37755589/#:~:text=A%20total%20of%
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-approval-of-the-accuray-precision-treatment-planning-system-by-chinas-national-medical-products-administration-302170420.html
SOURCE Accuray Incorporated
FAQ
What is the Accuray Precision Treatment Planning System (TPS)?
What approval did Accuray receive from the Chinese NMPA?
What benefits does the Tomo C system provide?
How does the Accuray Precision TPS enhance treatment plans?
What is the significance of the Accuray TPS approval in China?
